Thrombotic thrombocytopenic purpura: Description and analysis of 23 cases treated in Chile between 2017 and 2022
Introduction Since the first description of Thrombotic Thrombocytopenic Purpura, caused by a severe deficiency of ADAMTS13, plasma exchange and immunosuppression have become standard treatments, allowing to decrease its high mortality rate. Prospective records of Thrombotic Thrombocytopenic Purpura...
Saved in:
| Main Authors: | Daniel Cathalifaud, Jean-Paul Manríquez, Benjamín Rodríguez, Gonzalo Eymin, Benjamín Sanfuentes, Joel Castellano, Andrés Valenzuela |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medwave Estudios Limitada
2025-07-01
|
| Series: | Medwave |
| Subjects: | |
| Online Access: | https://www.medwave.cl/investigacion/estudios/3002.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical presentation and treatment of thrombotic thrombocytopenic purpura - analysis of recent diagnostic and therapeutic methods
by: Jan Szwech, et al.
Published: (2025-03-01) -
Caplacizumab in the Treatment of Patients with Recurrent Thrombotic Thrombocytopenic Purpura (TTP)
by: Mihaela-Sabrina HERDEA, et al.
Published: (2025-03-01) -
Thrombotic Thrombocytopenic Purpura as a Rare Etiopathogenetic Cause of Cerebral Infarction and Extracerebral Thrombosis
by: А. R. Аvidzba, et al.
Published: (2021-08-01) -
Prophylactic use of recombinant ADAMTS-13 during pregnancy for congenital thrombotic thrombocytopenic purpura
by: Éloïse Colliou, et al.
Published: (2025-01-01) -
A compound heterozygous ADAMTS13 mutation causes congenital thrombotic thrombocytopenic purpura: a case report
by: Yezi Huang, et al.
Published: (2025-01-01)